Search

Your search keyword '"Saad Albichr, Imane"' showing total 2 results
Start Over Author "Saad Albichr, Imane" Topic sars-cov-2
2 results on '"Saad Albichr, Imane"'

1. T-cell and Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients.

Author

Devresse A, Saad Albichr I, Georgery H, Yombi JC, De Greef J, Belkhir L, Mzougui S, Scohy A, Darius T, Buemi A, Goffin E, Kabamba B, and Kanaan N

Subjects
Adult, Aged, BNT162 Vaccine, Belgium, COVID-19 immunology, COVID-19 virology, Female, Humans, Immunity, Humoral drug effects, Immunization Schedule, Immunocompromised Host, Immunosuppressive Agents adverse effects, Interferon-gamma metabolism, Lymphocyte Activation drug effects, Male, Middle Aged, Prospective Studies, SARS-CoV-2 pathogenicity, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes virology, Time Factors, Antibodies, Viral blood, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Immunogenicity, Vaccine, Kidney Transplantation adverse effects, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, T-Lymphocytes drug effects, Vaccination
Abstract

Competing Interests: The authors declare no funding or conflicts of interest.

Published
2021
Full Text
View/download PDF

2. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?

Author

Saad Albichr, Imane, De Greef, Julien, Van Den Neste, Eric, Poiré, Xavier, Havelange, Violaine, Vekemans, Marie-Christiane, Bailly, Sarah, Yombi, Jean-Cyr, Mzougui, Samy, Scohy, Anaïs, and Kabamba-Mukadi, Benoît

Subjects
*HUMORAL immunity, *SEROCONVERSION, *COVID-19 vaccines, *HEMATOLOGIC malignancies, *VACCINE effectiveness, *CORONAVIRUS diseases
Abstract

At present, SARS-CoV-2 vaccines have shown excellent efficacy to prevent COVID-19 but immunocompromised patients were left-off most vaccine clinical trials albeit their extreme vulnerability [[1]]. Several studies showed that patients with HM, particularly lymphoid malignancies, had a lower antibody response to COVID-19 vaccines than general population and might be left unprotected from SARS-CoV-2 infection [[3], [5]]. Keywords: COVID-19; SARS-CoV-2; vaccine; cellular immunity; hematologic malignancies EN COVID-19 SARS-CoV-2 vaccine cellular immunity hematologic malignancies 743 746 4 03/07/22 20220301 NES 220301 SARS-CoV-2 vaccines offered great hope in controlling the worldwide COVID-19 pandemic. At initiation of vaccination against COVID-19, 10 patients were receiving ibrutinib, 5 patients were receiving anti-CD20 treatments (4 rituximab and 1 obinutuzumab), including 3 patients receiving a combination of ibrutinib and rituximab. [Extracted from the article]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results